Year Founded
2008
Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Small moleculeSmall molecule

Genosco General Information

FDA approved lazertinib (Leclaza) in combination with amivantamab for NSCLC. Has multiple kinase inhibitor programs in development.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office

Drug Pipeline

lazertinib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Genosco's pipeline data

Book a demo

Key Partnerships

Johnson & Johnson, Yuhan, Oscotec

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Genosco Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Genosco's complete valuation and funding history, request access »